Aflofarm's history
Aflofarm was established in 1989 in Pabianice as Aflopa. Since then, the company has been climbing the pharmaceuticals rankings every year to ultimately become the leader of the OTC market in 2012.
Learn about the growth of one of the biggest pharmaceutical companies in Poland
1989
Did you know...
In 1991 the company invests its initial funds in production of drugs and pharmaceuticals. In late 1991, the Ministry of Health and Welfare issued a license for production of the first formulation, Mentho-Paraffinol. The Galen Laboratory launched production in rented space in Ksawerów.
1991
1994
1995
Did you know...
The Drug Factory in Rzgów was launched in December 1994 with the production capacity of 1 million packages per month. The construction concept was based on the Good Manufacturing Practices (GMP) of the innovative pharmaceuticals industry. Today, the plant specializes in production of liquid forms (including syrups and suspensions).
1998
1999
Did you know...
Today, Aflofarm has up to 125 OTC drugs (over the counter) and more than 60 RX (prescription) medicines*. This makes Aflofarm one of the largest Polish drug manufacturers. *1.08.2024
2001
Did you know...
Today, Aflofarm has up to 125 OTC drugs (over the counter) and more than 60 RX (prescription) medicines*. This makes Aflofarm one of the largest Polish drug manufacturers. *1.08.2024
2002
2005
2006
2010
2012
2013
2016
Did you know...
Whenever we release new products, we do so for the benefit of our consumers. Through careful market analysis, we strive to offer them specific added value in addition to the solution to their problem. Diohespan, for example, was the first product in Poland containing 1000 mg of diosmin to allow for reduction of the number of taken pills. For more information about Aflofarm's innovative products, please click on the R&D tab.
Did you know....
The introduction of OTC cytisine and implementation of a broad advertising campaign for our product produced a significant increase in citazine consumption in Poland and was presumably the main reason for five hu8ndred thousand people quitting smoking between 2013 and 2014 (W. Zatonski, M. Zatonski). Research shows cylazine was used by 2.6 million people since 2005, about 30% of all smokers (Tutka, Wahl, Dąbrowa, Błażej).